PriceTargets.com logo

Legend Biotech - LEGN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $81.54
  • Forecasted Upside: 139.26%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$34.08 As of 12/20/2024 06:31 PM ET
▲ +0.06 (0.18%)

This chart shows the closing price for LEGN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Legend Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LEGN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LEGN

Analyst Price Target is $81.54
▲ +139.26% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Legend Biotech in the last 3 months. The average price target is $81.54, with a high forecast of $94.00 and a low forecast of $60.00. The average price target represents a 139.26% upside from the last price of $34.08.

This chart shows the closing price for LEGN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 13 polled investment analysts is to buy stock in Legend Biotech. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 13 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
12/9/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$83.00 ➝ $83.00
12/9/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
10/29/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00
10/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
10/8/2024Redburn AtlanticInitiated CoverageBuy$86.00
9/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
9/27/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00
8/28/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
8/12/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00
8/12/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$70.00 ➝ $76.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
7/18/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$65.00 ➝ $70.00
7/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
7/15/2024TD CowenLower TargetBuy ➝ Buy$71.00 ➝ $67.00
7/3/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00
7/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
6/21/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$86.00 ➝ $86.00
6/17/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$90.00 ➝ $90.00
6/17/2024Truist FinancialInitiated CoverageBuy$88.00
6/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00
5/24/2024HC WainwrightLower TargetBuy$86.00 ➝ $73.00
5/23/2024Deutsche Bank AktiengesellschaftInitiated CoverageBuy$60.00
5/14/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$85.00 ➝ $86.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00 ➝ $87.00
4/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
4/17/2024ScotiabankUpgradeSector Perform ➝ Sector Outperform$65.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
4/3/2024Cantor FitzgeraldInitiated CoverageOverweight$82.00
4/1/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
3/18/2024HC WainwrightReiterated RatingBuy ➝ Buy$87.00
3/18/2024UBS GroupBoost TargetBuy ➝ Buy$76.00 ➝ $81.00
3/13/2024Raymond JamesInitiated CoverageOutperform$86.00
3/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$85.00
1/24/2024BarclaysBoost TargetOverweight ➝ Overweight$93.00 ➝ $94.00
12/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$87.00
12/19/2023ScotiabankInitiated CoverageSector Perform$65.00
11/15/2023HC WainwrightBoost TargetBuy ➝ Buy$86.00 ➝ $87.00
11/6/2023The Goldman Sachs GroupInitiated CoverageBuy$90.09
10/18/2023BarclaysBoost TargetOverweight ➝ Overweight$92.00 ➝ $93.00
10/18/2023HC WainwrightBoost TargetBuy ➝ Buy$85.00 ➝ $86.00
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$85.00
8/2/2023CitigroupInitiated CoverageBuy
7/21/2023HC WainwrightBoost TargetBuy$82.00 ➝ $85.00
7/21/2023BarclaysBoost TargetOverweight$90.00 ➝ $92.00
7/20/2023Morgan StanleyBoost TargetOverweight$65.00 ➝ $85.00
6/12/2023BTIG ResearchBoost Target$85.00 ➝ $90.00
6/6/2023HC WainwrightBoost Target$77.00 ➝ $82.00
5/25/2023William BlairInitiated CoverageMarket Perform$64.00
5/22/2023Daiwa Capital MarketsInitiated CoverageBuy
5/19/2023Royal Bank of CanadaBoost Target$74.00 ➝ $83.00
5/19/2023BarclaysBoost Target$65.00 ➝ $90.00
4/25/2023BMO Capital MarketsBoost Target$79.00 ➝ $90.00
4/20/2023BTIG ResearchBoost TargetBuy$75.00 ➝ $85.00
4/20/2023HC WainwrightBoost TargetBuy$66.00 ➝ $77.00
4/19/2023JPMorgan Chase & Co.Boost TargetOverweight$65.00 ➝ $76.00
4/12/2023HC WainwrightReiterated RatingBuy$66.00
3/29/2023HC WainwrightInitiated CoverageBuy$66.00
3/24/2023Royal Bank of CanadaInitiated CoverageOutperform$73.00
1/25/2023BarclaysBoost TargetOverweight$53.00 ➝ $65.00
1/24/2023Morgan StanleyBoost TargetOverweight$60.00 ➝ $65.00
12/20/2022Piper SandlerBoost TargetOverweight$72.00 ➝ $78.00
12/6/2022JPMorgan Chase & Co.Boost TargetOverweight$61.00 ➝ $65.00
12/6/2022UBS GroupInitiated CoverageBuy$66.00
11/1/2022Evercore ISIInitiated CoverageOutperform
11/1/2022CowenInitiated CoverageOutperform
11/1/2022CowenInitiated CoverageOutperform
10/31/2022GuggenheimInitiated CoverageNeutral
10/13/2022Morgan StanleyLower TargetOverweight$63.00 ➝ $60.00
7/15/2022Morgan StanleyBoost TargetOverweight$55.00 ➝ $63.00
7/8/2022BMO Capital MarketsReiterated RatingBuy$77.00
6/16/2022BMO Capital MarketsInitiated CoverageOutperform$77.00
3/15/2022BarclaysInitiated CoverageOverweight$53.00
3/7/2022Morgan StanleyBoost TargetOverweight$51.00 ➝ $55.00
3/1/2022BTIG ResearchBoost Target$65.00 ➝ $75.00
1/31/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$51.00
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight
12/21/2021Piper SandlerInitiated CoverageOverweight$66.00
10/12/2021Morgan StanleyBoost TargetOverweight$50.00 ➝ $51.00
10/8/2021BTIG ResearchBoost TargetBuy$55.00 ➝ $65.00
6/29/2021JPMorgan Chase & Co.Reiterated RatingBuy
5/17/2021BTIG ResearchInitiated CoverageBuy$55.00
4/19/2021Morgan StanleyLower TargetOverweight$55.00 ➝ $50.00
1/20/2021JPMorgan Chase & Co.Reiterated RatingBuy
8/11/2020Jefferies Financial GroupReiterated RatingBuy$47.00
7/1/2020Jefferies Financial GroupInitiated CoverageBuy$47.00
7/1/2020JPMorgan Chase & Co.Initiated CoverageOverweight$50.00
6/30/2020Morgan StanleyInitiated CoverageOverweight$55.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 9 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 21 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/22/2024
  • 14 very positive mentions
  • 25 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/21/2024
  • 19 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 19 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Legend Biotech logo
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Read More

Today's Range

Now: $34.08
Low: $33.76
High: $34.89

50 Day Range

MA: $41.14
Low: $33.01
High: $49.68

52 Week Range

Now: $34.08
Low: $32.50
High: $70.13

Volume

1,644,206 shs

Average Volume

1,139,630 shs

Market Capitalization

$6.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.08

Frequently Asked Questions

What sell-side analysts currently cover shares of Legend Biotech?

The following Wall Street analysts have issued stock ratings on Legend Biotech in the last twelve months: Barclays PLC, BMO Capital Markets, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, HC Wainwright, Piper Sandler, Raymond James, Redburn Atlantic, Royal Bank of Canada, Scotiabank, TD Cowen, Truist Financial Co., and UBS Group AG.
View the latest analyst ratings for LEGN.

What is the current price target for Legend Biotech?

0 Wall Street analysts have set twelve-month price targets for Legend Biotech in the last year. Their average twelve-month price target is $81.54, suggesting a possible upside of 139.3%. Barclays PLC has the highest price target set, predicting LEGN will reach $94.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $60.00 for Legend Biotech in the next year.
View the latest price targets for LEGN.

What is the current consensus analyst rating for Legend Biotech?

Legend Biotech currently has 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LEGN will outperform the market and that investors should add to their positions of Legend Biotech.
View the latest ratings for LEGN.

What other companies compete with Legend Biotech?

Other companies that are similar to Legend Biotech include Teva Pharmaceutical Industries, BeiGene, Moderna, Viatris and Summit Therapeutics. Learn More about companies similar to Legend Biotech.

How do I contact Legend Biotech's investor relations team?

Legend Biotech's physical mailing address is 2101 COTTONTAIL LANE, SOMERSET NJ, 08873. The company's listed phone number is 732-317-5050 and its investor relations email address is [email protected]. The official website for Legend Biotech is www.legendbiotech.com. Learn More about contacing Legend Biotech investor relations.